Petra Muus
About
In The Last Decade
Petra Muus
166 papers receiving 5.7k citations
Hit Papers
Peers
Comparison fields: 5 of 115
- Hematology 3.3k
- Immunology 2.6k
- Nephrology 1.4k
- Genetics 1.4k
- Molecular Biology 1.2k
Countries citing papers authored by Petra Muus
This map shows the geographic impact of Petra Muus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petra Muus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petra Muus more than expected).
Fields of papers citing papers by Petra Muus
This network shows the impact of papers produced by Petra Muus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petra Muus. The network helps show where Petra Muus may publish in the future.
Co-authorship network of co-authors of Petra Muus
This figure shows the co-authorship network connecting the top 25 collaborators of Petra Muus. A scholar is included among the top collaborators of Petra Muus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Petra Muus. Petra Muus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 17 | |
| 2 | 0 | |
| 3 | 1 | |
| 4 | 21 | |
| 5 | 9 | |
| 6 | 296 | |
| 7 | 24 | |
| 8 | Improvement in Fatigue With Eculizumab Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria (pnh) Occurs Independent of Changes in Anemia | 3 |
| 9 | The clinical benefit of eculizumab is demonstrable in all subpopulations of patients with paroxysmal nocturnal hemoglobinuria (PNH) with hemolysis | 1 |
| 10 | 63 | |
| 11 | Final analysis of a randomized study on the value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML | 2 |
| 12 | A randomized study on the value of Fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. A report from the Dutch-Belgian hemato-oncology cooperative group (HOVON) | 2 |
| 13 | Cytogenetic risk group and cytogenetic response predict outcome of patients with poor-risk mds and secondary aml treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups | 1 |
| 14 | Analysis of clonality by HUMARA PCR in high risk MDS patients before and after intensive anti-leukemic treatment | 1 |
| 15 | 14 | |
| 16 | 26 | |
| 17 | Comparison of quality of life (QOL) of patients with acute myelogenous leukemias (AML) in long-term first complete remission (CR) after bone marrow transplantation (BMT) - Allogeneic or autologous - Or intensive chemotherapy consolidation (ICC): EORTC-GIMEMA AML 8A study | 1 |
| 18 | Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent. | 18 |
| 19 | 36 | |
| 20 | 14 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.